Clinical ResearchHeart Rhythm DisorderReal-Life Observations of Clinical Outcomes With Rhythm- and Rate-Control Therapies for Atrial Fibrillation: RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation)
Key Words
Abbreviations and Acronyms
Cited by (0)
The registry has been funded by sanofi-aventis. Editorial support for final manuscript formatting and final editing was funded by sanofi-aventis. Dr. Camm is a consultant and lecturer for sanofi-aventis. Dr. Breithardt has served on advisory boards for Bayer Healthcare, Boehringer Ingelheim, MSD (Merck & Co.), and sanofi-aventis. Dr. Crijns has served on advisory boards for sanofi-aventis, AstraZeneca, and MEDACorp. Dr. Dorian is a consultant to and has received research support from sanofi-aventis and Boehringer Ingelheim. Dr. Kowey is a consultant to and speaker for sanofi-aventis. Dr. Le Heuzey is a consultant to and served on advisory boards for sanofi-aventis, Bristol-Myers Squibb, MEDACorp, Boehringer Ingelheim, MSD (Merck & Co.), Bayer Healthcare, Pfizer Inc., Servier, Daiichi-Sankyo, and Medtronic. Drs. Merioua and Pedrazzini are employees of sanofi-aventis. Dr. Prystowsky is a consultant to sanofi-aventis, Boehringer Ingelheim, Bard, Medtronic, Stereotaxis, and CardioNet and owns stock in and is a director of Stereotaxis and CardioNet. Dr. Schwartz is a consultant to sanofi-aventis. Dr. Torp-Pedersen has received research grants from sanofi-aventis and Cardiome and is a consultant to Cardiome, sanofi-aventis, and Merck & Co. Dr. Weintraub has received research grants from and has consulted and served on advisory boards for sanofi-aventis. C. Noel Bairey-Marz, MD, served as Guest Editor for this paper.